Atopic Dermatitis Drugs Market Report 2024 (Global Edition)

Global Atopic Dermatitis Drugs Market Report 2024 Market Size Split by Route of Administration (Injectable, Oral, Topical), by Drug Class (Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Bio...

Atopic Dermatitis Drugs Market Report Description

We have various report editions of Atopic Dermatitis Drugs Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive Landscape of the Atopic Dermatitis Drugs Market

The report offers the appropriate analysis of the key organizations/companies involved within the global Atopic Dermatitis market. It also includes a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others.

Atopic Dermatitis Drugs Industry news

For instance, in March 2020, Eucrisa was approved by the FDA for children over three years of age, thus increasing the revenue-generating capacity of the drug. Another prominent PDE4 in the pipeline is roflumilast by ArcutisBiotherapeutics. In January 2021, the company announced initiating a phase 3 trial of the drug. 

For instance, in April 2021, AbbVie announced the extension of SNDA for the review of RINVOQ for atopic dermatitis adolescent and adult patients. The PDUFA was extended till quarter 3 of 2021. 

(Source:https://www.prnewswire.com/news-releases/abbvie-announces-extension-of-review-for-supplemental-new-drug-application-of-upadacitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-301261596.htm)

Top Companies Market Share in Atopic Dermatitis Drugs Industry: (In no particular order of Rank)

• Sanofi
• AbbVie Inc.
• Regeneron Pharmaceuticals
• Inc.
• Pfizer Inc.
• AnaptysBio
• Inc.
• Incyte Corporation Eli Lilly and Company Novartis AG
• LEO Pharma A/S
• AstellasPharma Inc.
• Bristol-Myers Squibb Company
• Galderma S.A.
• Dermira
• Inc. (acquired by Eli Lilly and Company)
• Encore Dermatology
• Inc.
• Medimetriks Pharmaceuticals
• Inc.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Atopic Dermatitis Drugs Market

Which Region will dominate the Atopic Dermatitis Drugs Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024 and accounted for around 40% of the global revenue.The region boasts a well-established healthcare infrastructure and a high adoption rate of advanced therapeutic solutions. Key players in the pharmaceutical industry are actively involved in research and development to introduce innovative drugs, contributing to the market's expansion. Additionally, supportive government initiatives and a growing emphasis on personalized medicine further propel market growth.

Which Region is Expanding at the Fastest CAGR?

European countries prioritize patient-centric healthcare, contributing to a high adoption rate of cutting-edge medications. Government initiatives aimed at addressing dermatological disorders and promoting awareness further bolster market expansion. Key pharmaceutical companies in the region engage in strategic collaborations and partnerships to strengthen their market presence and innovation capabilities.

The current report Scope analyzes Atopic Dermatitis Drugs Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Atopic Dermatitis Drugs Market

According to Cognitive Market Research, the global Atopic Dermatitis Drugs Market size was estimated at USD 12684.2 Million, out of which North America is the major market with more than 40% of the global revenue with a market size of USD 5073.68 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.7% from 2024 to 2031.The region experiences a high prevalence of atopic dermatitis, and the market is marked by continuous research and development efforts, resulting in the introduction of innovative therapies. The Injectable segment is expected to play a pivotal role in shaping the future landscape of Atopic Dermatitis Drugs, offering patients and healthcare providers effective and well-tolerated treatment options.In conclusion, North America's Atopic Dermatitis Drugs market continues to evolve, driven by a combination of high disease prevalence, advanced healthcare infrastructure, and a commitment to innovation.

Country Analysis

• According to Cognitive Market Research, the US had a major share in the Atopic Dermatitis Drugs Markets market with a market size of USD 4003.13 million in 2024 and is projected to grow at a CAGR of 6.5% during the forecast period. The USA market remains dynamic, with ongoing product innovations and adaptations to cater to the diverse needs of outdoor enthusiasts.
• The Canada Atopic Dermatitis Drugs Markets market had a market share of USD 608.84 million in 2024 and is projected to grow at a CAGR of 7.5% during the forecast period. The Canadian market remains dynamic, with ongoing product innovations addressing consumer needs and safety standards.
• The Mexico Atopic Dermatitis Drugs Markets market is projected to witness growth at a CAGR of 7.2% during the forecast period, with a market size of USD 461.70 million in 2024.

Europe Atopic Dermatitis Drugs Market

According to Cognitive Market Research, with a market value of USD 12684.2 million in 2024, it is projected to expand at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2031. Europe accounted for a share of over 30% of the global market size of USD 3805.26 million. The region's well-established healthcare infrastructure and emphasis on research and development contribute to the introduction of novel drugs, fostering market expansion. European countries prioritize patient-centric healthcare, leading to a high adoption rate of advanced medications. The Oral segment in the Atopic Dermatitis Drugs market is witnessing notable growth as oral medications play a crucial role in managing atopic dermatitis, especially in cases ranging from mild to moderate severity. In conclusion, the Atopic Dermatitis Drugs market in Europe is poised for continued expansion, driven by a combination of epidemiological factors, healthcare infrastructure, and collaborative efforts within the pharmaceutical industry.

• The United KingdomAtopic Dermatitis Drugs Markets market had a market share of USD 639.28 million in 2024 and is projected to grow at a CAGR of 7.8% during the forecast period. The UK market remains dynamic, with continuous product innovations and adaptations to meet the evolving needs of outdoor enthusiasts.
• The FranceAtopic Dermatitis Drugs Markets market is projected to witness growth at a CAGR of 6.2% during the forecast period, with a market size of USD 350.08 million in 2024.
• According to Cognitive Market Research, the German Atopic Dermatitis Drugs Market size was valued at USD 753.44 million in 2024 and is projected to grow at a CAGR of 7.2% during the forecast period. German consumers appreciate the convenience, portability, and quick heating features of these stoves for various outdoor activities, contributing to a growing demand.
• The ItalyAtopic Dermatitis Drugs Markets market is projected to witness growth at a CAGR of 6.4% during the forecast period, with a market size of USD 327.25 million in 2024.
• The Russian Atopic Dermatitis Drugs market is projected to witness growth at a CAGR of 6.0% during the forecast period, with a market size of USD 789.82 million in 2024.
• The SpainAtopic Dermatitis Drugs Markets market is projected to witness growth at a CAGR of 6.1% during the forecast period, with a market size of USD 312.03 million in 2024.
• The LuxembourgAtopic Dermatitis Drugs Market is projected to witness growth at a CAGR of 7.1% during the forecast period with a market size of USD 117.96 million in 2024.
• The PortugalAtopic Dermatitis Drugs Markets market is projected to witness growth at a CAGR of 6.8% during the forecast period, with a market size of USD 79.91 million in 2024.
• The GreeceAtopic Dermatitis Drugs Markets market is projected to witness growth at a CAGR of 7.3% during the forecast period, with a market size of USD 45.66 million in 2024.
• The rest of the European apps markets market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 589.82 million in 2024.

 

Asia Pacific Atopic Dermatitis Drugs Market

According to Cognitive Market Research, the global Atopic Dermatitis Drugs Market size was estimated at USD 12684.2 Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 2917.37 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.5% from 2024 to 2031. The region's rapidly expanding healthcare infrastructure and growing healthcare expenditure contribute to the market's development. The corticosteroids segment includes topical corticosteroids, which are commonly prescribed for mild to moderate cases, and systemic corticosteroids for more severe conditions. In conclusion, the Asia Pacific Atopic Dermatitis Drugs market presents vast opportunities for growth and innovation.

• According to Cognitive Market Research, the China Atopic Dermatitis Drugs Markets market size was valued at USD 1312.81 million in 2024 and is projected to grow at a CAGR of 10.0% during the forecast period. Chinese consumers value the convenience, portability, and quick heating features of these stoves for various outdoor activities, contributing to a rising demand.
• The JapanAtopic Dermatitis Drugs Markets market is projected to witness growth at a CAGR of 9.0% during the forecast period, with a market size of USD 402.60 million in 2024.
• The IndiaAtopic Dermatitis Drugs Markets market had a market share of USD 12.3 million in 2024 and is projected to grow at a CAGR of 6.3% during the forecast period. The Indian market remains dynamic, with continuous product innovations and adaptations to cater to the evolving needs of outdoor enthusiasts.
• The South Korean Topic Dermatitis Drugs Markets market is projected to witness growth at a CAGR of 9.6% during the forecast period, with a market size of USD 291.74 million in 2024.
• The AustraliaAtopic Dermatitis Drugs Markets market is projected to witness growth at a CAGR of 10.2% during the forecast period, with a market size of USD 151.70 million in 2024.
• The South East AsiaAtopic Dermatitis Drugs Markets market is projected to witness growth at a CAGR of 11.5.% during the forecast period, with a market size of USD 201.30 million in 2024.
• The rest of the Asia Pacific Topic Dermatitis Drugs market is projected to witness growth at a CAGR of 10.3% during the forecast period, with a market size of USD 201.13 million in 2024.

 

South America Atopic Dermatitis Drugs Market

According to Cognitive Market Research, the global Atopic Dermatitis Drugs Markets market size was estimated at USD 12684.2 Million, out of which the Latin America market has more than 5% of the global revenue with a market size of USD 634.21 million in 2024 and will grow at compound annual growth rate (CAGR) of 7.9% from 2024 to 2031.The region's pharmaceutical industry is actively involved in research and development, aiming to introduce effective and tailored solutions for atopic dermatitis.The Retail Pharmacies segment plays a crucial role in the Atopic Dermatitis Drugs market, serving as a primary distribution channel for medications. Retail Pharmacies provide a convenient and accessible platform for patients to obtain prescribed atopic dermatitis drugs, including topical corticosteroids, calcineur in inhibitors, and other oral or injectable treatments. In conclusion, Latin America is positioned to contribute significantly to the global Atopic Dermatitis Drugs market, providing diverse and effective solutions for patients in the region.

• According to Cognitive Market Research, the Brazil Atopic Dermatitis Drugs Markets market size was valued at USD 271.44 million in 2024 and is projected to grow at a CAGR of 8.5% during the forecast period. The Brazilian market remains dynamic, with continuous product innovations and adaptations to meet the evolving needs of outdoor enthusiasts.
• The ArgentinaAtopic Dermatitis Drugs Markets market had a market share of USD 106.55 million in 2024 and is projected to grow at a CAGR of 8.8% during the forecast period. The Argentine market remains dynamic, with continuous product innovations and adaptations to meet the evolving needs of outdoor enthusiasts.
• The ColombiaAtopic Dermatitis Drugs Markets market is projected to witness growth at a CAGR of 7.7% during the forecast period with a market size of USD 56.44 million in 2024.
• The PeruAtopic Dermatitis Drugs Markets market is projected to witness growth at a CAGR of 8.1% during the forecast period, with a market size of USD 52.01 million in 2024.
• The ChileAtopic Dermatitis Drugs Markets market is projected to witness growth at a CAGR of 8.2% during the forecast period, with a market size of USD 45.66 million in 2024.
• The rest of the Latin AmericaAtopic Dermatitis Drugs market is projected to witness growth at a CAGR of 7.0% during the forecast period, with a market size of USD 102.11 million in 2024.

 

Middle East and Africa Atopic Dermatitis Drugs Market

According to Cognitive Market Research, the global Atopic Dermatitis Drugs Market size was estimated at USD 12684.2 Million, out of which the Middle East and Africa are the major markets of around 2% of the global revenue with a market size of USD 253.68 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.2% from 2024 to 2031.The region is witnessing a rise in the prevalence of atopic dermatitis, attributed to environmental factors and lifestyle changes. Governments in the MEA region are progressively investing in healthcare, fostering the development of dermatological services and contributing to the market's expansion. Calcineurin Inhibitors offer an alternative with a lower risk of skin atrophy. This segment is particularly valuable for sensitive areas like the face and neck. In conclusion, the Atopic Dermatitis Drugs market in the MEA region shows promise, with a burgeoning awareness of dermatological health and increasing investments in healthcare infrastructure.

• According to Cognitive Market Research, the GCC Countries Atopic Dermatitis Drugs Markets market size was valued at USD 108.58 million in 2024 and is projected to grow at a CAGR of 9.0% during the forecast period. GCC appreciates the portability, versatility, and quick heating features of these stoves for various outdoor activities, from desert camping to beach picnics.
• The EgyptAtopic Dermatitis Drugs Markets market is projected to witness growth at a CAGR of 8.5% during the forecast period, with a market size of USD 26.64 million in 2024.
• The South AfricaAtopic Dermatitis Drugs Markets market is projected to witness growth at a CAGR of 9.2% during the forecast period, with a market size of USD 40.08 million in 2024. South African consumers appreciate the portability, versatility, and quick heating features of these stoves for various outdoor activities, from camping safaris to beach outings.
• The TurkeyAtopic Dermatitis Drugs Markets market is projected to witness growth at a CAGR of 7.7% during the forecast period, with a market size of USD 21.82 million in 2024.
• The NigeriaAtopic Dermatitis Drugs Markets market is projected to witness growth at a CAGR of 7.3% during the forecast period, with a market size of USD 26.64 million in 2024.

 

Atopic Dermatitis Drugs Market Analysis

Atopic Dermatitis Drugs Market Route of Administration Segment Analysis

According to Cognitive Market Research, Injectable formulations, such as biologics and monoclonal antibodies, have gained prominence for their ability to directly target specific inflammatory pathways associated with atopic dermatitis, providing patients with more effective and sustained relief. The convenience of injectable administration, often in the form of subcutaneous or intravenous injections, enhances patient compliance and facilitates regular treatment schedules.

The oral segment offers convenience to patients, allowing them to administer medications orally, thereby promoting better adherence to treatment regimens. Pharmaceutical companies are actively engaged in developing new oral formulations and improving existing ones to enhance efficacy and minimize side effects.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Atopic Dermatitis Drugs Industry. Request a Free Sample PDF!

Atopic Dermatitis Drugs Market Drug Class Segment Analysis

According to Cognitive Market Research, Corticosteroids exert anti-inflammatory effects, making them effective in alleviating itching, redness, and swelling. This segment includes topical corticosteroids, which are commonly prescribed for mild to moderate cases, and systemic corticosteroids for more severe conditions. Despite their effectiveness, long-term use of systemic corticosteroids may lead to side effects, prompting ongoing research into safer and targeted formulations.

Calcineurin Inhibitors offer an alternative with a lower risk of skin atrophy. This segment is particularly valuable for sensitive areas like the face and neck. Ongoing research focuses on refining formulations and understanding the long-term safety of these inhibitors.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Atopic Dermatitis Drugs Distribution Channel Segment Analysis

According to Cognitive Market Research, Hospital Pharmacies segment facilitate immediate access to treatments during emergency situations and cater to the specific needs of patients with severe or acute atopic dermatitis cases. Additionally, they contribute to comprehensive patient care by collaborating closely with healthcare professionals, ensuring proper medication management, and monitoring treatment outcomes.

Retail Pharmacies provide a convenient and accessible platform for patients to obtain prescribed atopic dermatitis drugs, including topical corticosteroids, calcineurin inhibitors, and other oral or injectable treatments. These pharmacies offer personalized patient counseling, aiding in proper medication administration and adherence.

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion